SCHEMBL4527623

SCHEMBL4527623

CCn1cnc2c(=O)n(-c3ccc(F)cc3)c(Cc3ccc(F)cc3Cl)nc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
USP7 Q93009 1/20 0.38
HKDC1 Q2TB90 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAT2A P31153 1/20 0.38
CNR2 P34972 2/20 0.37
LMNA P02545 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
HPGD P15428 2/20 0.37
TSHR P16473 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
MAOB P27338 1/20 0.36
GSR P00390 1/20 0.36
KMT2A Q03164 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4530159 0.94 MAT2A (0.43) MAPK1NPSR1USP7HKDC1SMN1; SMN2
SCHEMBL4531050 0.90 SMN1; SMN2 (0.42) MAPK1NPSR1USP7HKDC1SMN1; SMN2
SCHEMBL4531589 0.90 HKDC1 (0.39) HKDC1SMN1; SMN2MAT2ALMNANPC1
SCHEMBL4519094 0.89 MAPK1 (0.47) MAPK1NPSR1USP7HKDC1SMN1; SMN2
SCHEMBL4507591 0.88 MAT2A (0.43) USP7HKDC1SMN1; SMN2MAT2ALMNA
SCHEMBL4521476 0.88 GSR (0.39) NPSR1HKDC1SMN1; SMN2MAT2ALMNA
SCHEMBL4529801 0.88 SMN1; SMN2 (0.39) HKDC1SMN1; SMN2MAT2ALMNANPC1
SCHEMBL4522510 0.87 GSR (0.40) NPSR1HKDC1SMN1; SMN2MAT2ALMNA
SCHEMBL4522632 0.86 HKDC1 (0.39) MAPK1USP7HKDC1SMN1; SMN2MAT2A
SCHEMBL4521974 0.86 SMN1; SMN2 (0.39) HKDC1SMN1; SMN2MAT2ALMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298856-A1 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) BROWN REBECCA ELIZABETH 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298856-A1 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) TRPV1, TRPV2, TRPV4 MAPK1 1197/4885NPSR1 102/4885USP7 4696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.